Microbial community compositions in breast implant biofilms associated with contracted capsules

Sean A. Crowe1*, Rachel L. Simister1, Jenifer S. Spence1, Paul A. Kenward1, Aaron C. Van Slyke2, Peter Lennox2,3, Nick Carr4*

1 Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada, 2 Department of Surgery, University of British Columbia, Vancouver, BC, Canada, 3 Vancouver Plastic Surgery, Vancouver, BC, Canada, 4 Skinworks, Vancouver, BC, Canada

* seancrowe@ubc.ca (SC); drcarr@skinworks.ca (NC)

Abstract

Subclinical bacterial infections (biofilms) are strongly implicated in breast augmentation failure due to capsular contracture, and while these infections are generally ascribed to common skin commensals, this remains largely unsubstantiated through robust cultivation independent analyses. To determine capsule biofilm microbial community compositions, we employed amplicon sequencing of the 16S rRNA gene using DNA extracted from breast implant capsule samples. These cultivation independent analyses revealed that capsule associated biofilms are more diverse than canonical single-species infections, but have relatively low diversity (~<100 species) compared to many host-associated microbial communities. In addition to taxa commonly associated with capsular contracture, the biofilms analyzed comprised a number of taxa that escaped detection in cultivation-dependent work. We have also isolated several key taxa identified through the culture-independent analyses. Together our analyses reveal that capsule biofilms are more diverse than cultivation studies suggest and can be heterogeneous within an individual capsule, between breasts of the same patient, across similar implant types, and over a range in severity of contracture. The complex nature of these communities requires further study across a broader suite of patients in addition to higher resolution analyses including metagenomics to better assess the fundamental role of microorganisms in capsular contracture.

Introduction

The human body is comprised of more than one microbial cell for every human cell [1] and these microbial cells, the human microbiome, are both taxonomically and physiologically diverse. The metabolic blueprint that codes for healthy human physiology is distributed across more than 2000 Mb (assuming more than 1000 species with mean genome sizes of 2 Mb) of non-redundant microbial genomic information in addition to the 3200 Mb of the human genome [2]. This hidden majority of microbial cells and genomic information often plays an outsized role in human health impacting inflammation, immunity, and a vast array of acute...
PL are also employed at Skin Works and Vancouver Plastic Surgery, respectively. Skin Works and Vancouver Plastic Surgery provided income for NC and PL as well as matching funds for NSERC engage grant 488438. NC and PL helped design sampling methodology and provided sample materials along with patient metadata. They also had roles in data interpretation, manuscript preparation and decision to publish.

Competing interests: NC and PL are also employed at Skin Works and Vancouver Plastic Surgery, respectively. Skin Works and Vancouver Plastic Surgery provided income for NC and PL as well as matching funds for NSERC engage grant 488438. We have no competing interests and our commercial affiliations do not alter our adherence to PLOS One policies on sharing data and materials.

Illness related to microbe-host interactions (dysbiosis) is best thought of as a disruption to the composition and activity of the healthy microbiome. Surgical procedures, including implantation, often cause dysbiosis as a result of immune responses, introduced microbial community members, or the alteration of the physical-chemical properties of the tissue environment. Colonization of surgical implants by microorganisms, both innate and foreign, and the subsequent development of microbial biofilms on implant surfaces often leads to complications including inflammation and other immune responses, implant failure, or disruption of optimal wound healing and scar tissue formation [10]. Prevention of implant biofilm formation currently relies on a range of poorly informed interventions including treatment with antibiotics of varying specificity that target putative biofilm community members [11–13]. Historically, these community members have been identified through cultivation dependent methodologies, despite cultivation being notoriously biased against key community members that remain undetected [14], thereby confounding interventions intended to improve health. New cultivation-independent methods overcome these biases and yield a more complete and accurate description of relevant microbial community members [15] and their potential physiology and function [16]. As these approaches are increasingly applied to the microbiome, we are gaining an appreciation for the roles different community members play in healthy and unhealthy tissue-microbiome functioning [17]. Cultivation-independent approaches remain under-applied, however, to the vast array of surgical implant complications that plague the medical community.

All implanted foreign bodies induce a host reaction consisting of production of a capsular layer that surrounds the foreign material. In the case of breast implants, the capsule can vary from soft and pliable (Baker grade I) to a pathologic contracted layer causing the implant to become distorted, hard, and painful (Baker grade IV) [12, 18–20]. Capsular contracture is the most common complication following breast augmentation surgeries and these are among the most widely performed surgical implantations. Subclinical bacterial infections (biofilms) are strongly implicated in capsular contracture [21, 22], and while these infections are generally ascribed to common skin commensals, this remains largely unsubstantiated through robust cultivation-independent analyses. Notably, capsular contracture and associated biofilm formation are now also potentially linked to Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA_ALCL) [23–25]. While capsular contracture represents a critical human health challenge, conventional preventative measures such as irrigation with antibiotics remain only partially effective in its prevention, in part because the bacteria responsible for biofilms are highly resistant to many antibiotics [26]. New preventative measures are, therefore, needed to reduce the incidence of this complication [27, 28].

Staphylococcus epidermidis has been implicated in biofilm formation on implant capsules based on its recovery in standard culture dependent medical studies [29], as well as related Staphylococcus taxa in newer culture-independent studies [30, 31]. S. epidermidis is classically considered non-pathogenic, though it is increasingly associated with sub-clinical infections, in particular those involving prosthetic devices [32–34]. While Staphylococcus sp. almost certainly play a role in the formation of capsular biofilms [35, 36], they likely do so within a broader ecological context defined by other community members that evade detection through cultivation, as indicated through culture independent analyses [30, 31]. Detailed information on the composition of the microbial communities from contracted capsules is thus a much-needed first step towards diagnosing the causative microbial agents in capsular biofilm formation and chronic human health issues [3–6]. Considerable efforts are underway to map the diversity, metabolic potential, and ecological principles that define interactions within the human microbiome and between the microbiome and the human host to inform translational outcomes across the health sector [7–9].
innovating new solutions for prevention and treatment of capsular contracture. Our combined cultivation-dependent and independent approach reveals that biofilms from pathological and non-pathological contracted capsules comprise diverse microbial communities, including many members that were undetected in cultivation-based studies.

Results

High quality DNA was recovered from all samples, but some samples (Table 1) did not yield amplicons of either bacterial or archaeal 16S rRNA genes, even through nested PCR amplification. Microbial DNA was successfully detected, defined as a positive amplification of the 16S rRNA gene, in capsules from 14 of 17 patients, or in more than 80% of cases. Bacterial loads were quantified through qPCR of the 16S rRNA gene and ranged from $1 \times 10^5$ to $5 \times 10^7$ copies g$^{-1}$ of tissue extracted (Table 1). We also tested for inhibition of gene amplification commonly observed when the target template is strongly diluted by non-target DNA or by other organic compounds (Table 2). These tests reveal that our qPCR results may underestimate total 16S rRNA gene copies by as much as a factor of 100. Our qPCR-based estimates of bacterial loads should thus be considered minimum loads. Corresponding DNA extraction blanks ranged from $10^2$ to $10^6$ copies g$^{-1}$, assuming a nominal extraction mass of 0.2 g. The abundance of bacterial 16S rRNA gene copies recovered from capsule and tissue was, therefore, at least 2 orders of magnitude higher than that present in the reagents used in DNA extraction, purification, and PCR, and we therefore concluded that contamination from extraction was negligible.

Amplicon sequencing of 16S rRNA gene copies from low biomass samples can also be prone to contamination associated with library preparation. To evaluate such contamination in our data we sequenced both our extraction and PCR blanks, which mostly yielded sequences affiliated to the Proteobacteria, Firmicutes, and Actinobacteria phyla. To correct microbial community profiles for such possible contamination, we proportionally removed reads from samples based on the relative abundances of sequences recovered from our extraction blanks. The most abundant sequence in the blank was used to estimate the fraction of reads in a sample that could have resulted from contamination, conservatively assuming all sample reads with that sequence were derived from contamination. We then subtracted reads from other sequences based on their proportional abundance in the blank. This blank correction can be written as:

$$S_{corr} = S - S_{max} \cdot \frac{B}{B_{max}}$$

Where $S_{corr}$ is the blank corrected read count for a given sequence, $S$ is the raw read count for the same sequence, $S_{max}$ is the sample read count of the most abundant sequence in the extraction blank (in this case *E. coli*), $B$ is the read count for a given sequence in the blank, and $B_{max}$ is the read count of the most abundant sequence in the blank. On average this blank correction decreased the number of observed sequences by 4%, and at a maximum, it decreased the number of observed sequences by 16%. We thus refer to this blank corrected data throughout the rest of the paper.

Replicate (5–6) analyses of microbial community composition were conducted on 4 contracted capsules, with a range in bacterial loads, and the degree of heterogeneity within a given contracted capsule was variable (Fig 1). Of the 4 capsules evaluated, 2 of these exhibited identical communities, at the phylum level, across 5 separate extractions (Fig 1A). Capsule C2R was largely comprised of Actinobacteria of the *Rhodococcus* species (sp.) (range 99.8–99.9%), while capsule C7L was largely comprised of Firmicutes of the unclassified Bacillales sp. (range 99.7–99.8%) (Fig 1B), across the 5 replicates analyzed. The 2 other capsules evaluated were
Table 1. Capsular samples, qPCR quantification of the capsular tissue microbial load (gene copies per gram of tissue), respective number of sequences analyzed, observed sequences, chao 1 alpha diversity indices, implant type, and Baker scale rating.

| Sample ID | qPCR (copies/g) | Total number of OTUs | Chao1 | Implant Type | Implant Plane | Baker Scale Grade | Aesthetic v Recon (A v R) | Yrs in place | Age range (decade) at last surgery | BMI | Smoker | Reason for Surgery | Notes |
|-----------|-----------------|----------------------|-------|--------------|---------------|-------------------|--------------------------|--------------|------------------------------------|------|---------|-------------------|-------|
| C1L       | 4.33E+05        | 80                   | 97    | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C1L Rep. 1| 3.87E+05        | 83                   | 135   | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C1L Rep. 2| 7.73E+05        | 134                  | 138   | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C1L Rep. 3| 5.02E+05        | 157                  | 138   | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C1L Rep. 4| 4.51E+05        | 93                   | 98    | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C1L Rep. 5| 6.08E+05        | 92                   | 94    | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C1R†      | 1.11E+06        | 38                   | 61    | TAG-410      | Retro.        | 1                 | R                        | 8            | 70–80                              | 16   | N       | Malrotation       | Non-adherent |
| C2L       | 1.99E+07        | 21                   | 37    | TAG-410      | Retro.        | 1                 | A                        | 5            | 40–50                              | 24   | N       | Pain / Malrotation | Non-adherent |
| C2L Rep. 1| 5.64E+05        | 45                   | 107   | TAG-410      | Retro.        | 1                 | A                        | 5            | 40–50                              | 24   | N       | Pain / Malrotation | Non-adherent |
| C2L Rep. 2| 2.28E+07        | 48                   | 78    | TAG-410      | Retro.        | 1                 | A                        | 5            | 40–50                              | 24   | N       | Pain / Malrotation | Non-adherent |
| C2L Rep. 3| 1.79E+07        | 43                   | 141   | TAG-410      | Retro.        | 1                 | A                        | 5            | 40–50                              | 24   | N       | Pain / Malrotation | Non-adherent |
| C2L Rep. 4| 2.09E+07        | 16                   | 42    | TAG-410      | Retro.        | 1                 | A                        | 5            | 40–50                              | 24   | N       | Pain / Malrotation | Non-adherent |
| C3L       | 5.38E+05        | 79                   | 95    | SRG          | Sub.          | 4                 | A                        | 35           | 50–60                              | 24   | N       | Cap con / Bilateral rupture | Bilateral ER |
| C3L Rep. 1| 5.75E+05        | 31                   | 88    | SRG          | Sub.          | 4                 | A                        | 35           | 50–60                              | 24   | N       | Cap con / Bilateral rupture | Bilateral ER |
| C3L Rep. 2| 5.14E+05        | 131                  | 242   | TAG-410      | Retro.        | 1                 | A                        | 7            | 40–50                              | 21   | N       | Right rupture       | Non-adherent |
| C3L Rep. 3| 5.77E+05        | 71                   | 55    | TAG-410      | Retro.        | 1                 | A                        | 7            | 40–50                              | 21   | N       | Right rupture       | Non-adherent |
| C3L Rep. 4| 5.64E+05        | 78                   | 103   | TAG-410      | Retro.        | 1                 | A                        | 7            | 40–50                              | 21   | N       | Right rupture       | Non-adherent |
| C3L Rep. 5| 5.64E+05        | 112                  | 255   | TAG-410      | Retro.        | 1                 | A                        | 7            | 40–50                              | 21   | N       | Right rupture       | Non-adherent |
| C4L       | 4.19E+05        | 27                   | 34    | SRS          | Retro.        | 3                 | A                        | 2            | 30–40                              | 21   | N       | Ptosis             | Non-adherent |
| C4L Rep. 1| 4.90E+05        | 15                   | 40    | SRS          | Retro.        | 2                 | A                        | 15           | 50–60                              | 18   | N       | Ptosis             | Non-adherent |
| C4L Rep. 2| 9.03E+05        | 47                   | 54    | TAG-410      | Retro.        | 4                 | A                        | 7            | 40–50                              | 24   | N       | Cap con            | Partially-adherent double capsule |
| C4L Rep. 3| 4.21E+05        | 43                   | 24    | TAG-410      | Retro.        | 4                 | A                        | 7            | 40–50                              | 24   | N       | Cap con            | Partially-adherent double capsule |
| (Continued)
somewhat heterogeneous across the separate extractions. For example, of the 6 replicate analyses of capsule C1L, 4 were dominated by members of the Actinobacteria, 1 by Firmicutes, and 1 by Proteobacteria. Appreciable Bacteroidetes were only present in 1 replicate (Fig 1A). Similarly, replicates of capsule 4R were also variable, and while 3 of the 5 replicates were exclusively

Table 1. (Continued)

| Sample ID | qPCR (copies/g) | Total number of OTUs | Chaol | Implant Type | Implant Plane | Baker Scale Grade | Aesthetic v Recon (A v R) | Yrs in place | Age range (decade) at last surgery | BMI | Smoker | Reason for Surgery | Notes |
|-----------|----------------|----------------------|-------|--------------|---------------|-------------------|--------------------------|--------------|-----------------------------------|-----|---------|---------------------|-------|
| C7 Rep. 3 | 1.11E+06       | 43                   | 62    |              |               |                   |                          |              |                                   |     |         |                     |       |
| C7 Rep. 4 | 3.21E+06       | 69                   | 72    |              |               |                   |                          |              |                                   |     |         |                     |       |
| C7 Rep. 5 | 3.58E+06       | 60                   | 107   |              |               |                   |                          |              |                                   |     |         |                     |       |
| C8R       | 1.14E+07       | 79                   | -     | SRS          | Retro.        | 1                 | A                        | 12           | 30–40                             | 20  | N       | Size change / Mastopexy       |       |
| C9L       | 1.80E+06       | 65                   | 80    | TRG          | Retro.        | 2                 | A                        | 4            | 30–40                             | 20  | N       | Left peri-prosthetic fluid   |       |
| C9R       | 3.06E+05       | 58                   | 72    | TRG          | Retro.        | 2                 | A                        | 4            | 30–40                             | 20  | N       | Left peri-prosthetic fluid   |       |
| C10L      | NA             | NA                   | NA    | SRG          | Retro.        | 4                 | A                        | 36           | 80–90                             | 19  | Y       | Bilateral rupture (intracapsular) | Partially-adherent |
| C10R      | NA             | NA                   | NA    | SRG          | Retro.        | 3                 | A                        | 36           | 80–90                             | 19  | Y       | Bilateral rupture (intracapsular) |       |
| C11L      | 7.46E+05       | 67                   | 85    | SRG          | Retro.        | 3                 | A                        | 2            | 30–40                             | 24  | N       | Cap con                  |       |
| C11R      | 7.42E+05       | 68                   | 94    | SRG          | Retro.        | 1                 | A                        | 2            | 30–40                             | 24  | N       | Cap con                  |       |
| C12L      | 1.38E+05       | 157                  | 249   | SRS          | Retro.        | 2                 | A                        | 46           | 60–70                             | 18  | Y       | Cap con                  |       |
| C12R      | 8.14E+05       | 46                   | 57    | SRS          | Retro.        | 4                 | A                        | 46           | 60–70                             | 18  | Y       | Cap con                  | Calciﬁed |
| C13R      | 1.90E+06       | 109                  | 135   | SRG          | Retro.        | 3                 | A                        | 2            | 23                                |     | Y       | Cap con                  |       |
| C14L-A    | 1.18E+06       | 108                  | 133   | SRG          | Sub.          | 2                 | A                        | 15           | 40–50                             | 23  | N       | Lett rupture (intracapsular) / ptosis | IR; soft area |
| C14L-B    | 1.04E+06       | 57                   | 107   | SRG          | Sub.          | 2                 | A                        | 15           | 40–50                             | 23  | N       | Lett rupture (intracapsular) / ptosis | IR; calcified area |
| C14R      | 2.45E+06       | 41                   | -     | SRG          | Sub.          | 2                 | A                        | 15           | 40–50                             | 23  | N       | Lett rupture (intracapsular) / ptosis | Extracapsular rupture |
| C15L      | 2.21E+06       | 113                  | 135   | SRG          | Retro.        | 2                 | A                        | 8            | 30–40                             | 23  | N       | Malposition / Ptsion          |       |
| C15R      | 2.27E+06       | 42                   | 49    | SRG          | Retro.        | 2                 | A                        | 8            | 30–40                             | 23  | N       | Malposition / Ptsion          |       |
| C16L      | 2.88E+05       | 126                  | 396   | SRS          | Retro.        | 2                 | A                        | 24           | 60–70                             | 22  | N       | Deflated implants             | Deflated |
| C17L      | 4.41E+05       | 42                   | 49    | TAG          | Sub.          | 2                 | A                        | 9            | 30–40                             | 23  | N       | Malrotation               | Non-adherent |
| C17R      | 7.68E+05       | 218                  | 664   | TAG          | Sub.          | 2                 | A                        | 9            | 30–40                             | 23  | N       | Malrotation               | Non-adherent |

†All capsules were collected from aesthetic surgery, except sample 1, which comes from a reconstructive surgery.

TAG = Textured Anatomical Gel; TRG = Textured Round Gel; SRG = Smooth Round Gel; SRS = Smooth Round Saline; Retro. = Retropectoral; Sub. = Subglandular; ER = Extracapsular Rupture; IR = Intracapsular Rupture.

*C14L-A & C14L-B were sourced from the same capsule, however a portion of the capsule was calcified so the capsule was subsampled into “soft” and “calcified” portions and treated separately. NA = No Amplicons.

Blank-corrected values are presented for both observed sequences and chao 1. Note that Baker scales I and II are considered non-pathologic, whereas III and IV are pathologic.

https://doi.org/10.1371/journal.pone.0249261.1001
Proteobacteria, 1 was exclusively Actinobacteria and the other was mixed Proteobacteria and Firmicutes. At the species level (97% identity in the 16S rRNA gene) capsule C1L was dominated by *Rhodococcus* sp. (13.2–99.6%), *Enhydrobacter* sp. (up to 77.6% in a single replicate), and *Finegoldia* sp. (up to 85.8% in a single replicate) across 6 separate replicates (Fig 1B). In capsule C4R, there was a larger degree of variation at the species level between replicates, with the most abundant OTUs being the *Escherichia-shigella* sp. (0–99.8%), *Rhodococcus* sp. (0–99.1%), unclassified Burkholderiaceae sp. (0–99.6%), *Staphylococcus* sp. (41.0%) and *Acinetobacter* sp. (0–18.7%) (Fig 1B). Notably, both homogeneous capsules, C2R and C7L, had high bacterial loads, $10^6$–$10^7$ 16S rRNA gene copies g$^{-1}$, while the more heterogeneous capsules, C1L and C4R, had lower loads of $10^5$–$10^6$ rRNA gene copies g$^{-1}$ (Table 1).

Microbial community profiles based on 16S rRNA gene sequences recovered from a wider suite of contracted capsules comprised 3–4 principle phyla and 16–218 observed species (Fig 2A and 2B and Table 1). Rarefaction analyses revealed that resampling of the observed taxa approaches, but doesn’t quite reach, asymptotic values and thus may not capture the full diversity of the microbial communities (Fig 2C). Bacterial diversity metrics at the 97% sequence identity level estimate capsule microbial community taxonomic richness (Chao 1) of 24–664 species, or more (Table 1). Most capsule microbial community members belong to the Actinobacteria (0–99.9%), Firmicutes (0.01–99.9%), Proteobacteria (0–99.9%), and Bacteroidetes (0.01–17.3%) (Fig 2A). With a cutoff of >1% average abundance across all samples, 23 species remain (Fig 2B), and of these species, the top 6 most abundant represent a combined average of 49% of all sequences per sample, which were assigned to, *Staphylococcus* sp. (range 0–99% present in 15/24 samples), *Rhodococcus* sp. (range 0–83% present 15/24 samples), unclassified *Bacillales* sp. (range 0–92%, present in 17/24 samples), *Escherichia-shigella* sp. (range 0–48%, present in 9/24 samples), *Pseudomonas* sp. (range 0–99%, present 4/24 samples), and *Cutibacterium* sp. (0–98%, present in 16/24 samples) (Fig 2B). The other 18 species were present in a fewer number of samples, on average, and varied widely in abundance between samples (range 0–99%, present in $<5$/24 capsules).

To supplement our amplicon sequence data and initiate lab culture strains for follow-on physiological and genomic studies, we also isolated organisms from an arbitrarily selected subset of the capsules. Swabs of tissue or saline solutions remaining after tissue storage were streaked onto LB agar and incubated at 37°C. Pure isolates were selected for 16S rRNA gene sequencing to describe their taxonomy and relate the isolates to the cultivation-independent
characterization of the capsule communities. Our isolate collection is comprised exclusively of members of the Firmicutes and Actinobacteria (Fig 3A). At higher taxonomic resolution, our isolates were identified as *Rhodococcus* sp., *Bacillus* sp., *Staphylococcus* sp., and *Micrococcus* sp. (Fig 3B and 3C).

Microbial community profiles were compared to a limited number of variables related to implant type and degree of capsular contracture graded through the Baker scale. The Baker scale is defined as: Grade I in which the breast is normally soft and appears natural in size and shape; Grade II in which the breast is a little firm, but appears normal; Grade III in which the breast is firm and appears abnormal; and Grade IV in which the breast is hard, painful to the touch, and appears abnormal [37]. Baker Grade I and II capsules are not pathologic, while III and IV grades are more strongly contracted and therefore pathologic. A hierarchical clustering
analysis was used to test for relationships between implant type, plane of placement, and Baker contracture grade (Fig 4).

Discussion

In our study, more than 80% of capsules analyzed had amplifiable microbial 16S rRNA genes, which is comparable to, or higher than observations made in previous amplicon-based studies of capsular contracture (42% [30], and 8% [31]). Differences observed across studies likely reflect variations in methodological approaches. In particular, our use of nested PCR amplification to overcome PCR inhibitors from host material likely enhanced detectability in our study. Our documentation of strong PCR inhibition suggests that even appreciable bacterial loads may go undetected through standard amplicon-based analyses. Furthermore, our observations of variability, even at the scale of individual capsules, may ultimately manifest as differences in detectability across studies. We also note that careful contamination control is key for enabling robust microbiome detection.

Bacterial loads in contracted capsules ranged from $10^5$ to $10^7$ 16S rRNA gene copies g$^{-1}$ of capsular tissue. While 3 orders of magnitude lower than previous analyses of breast tissues [24], the bacterial loads studied here are much higher than our blanks and we can thus rule out reagent contamination, which is known to confound microbial community profiling based on amplicon sequencing, particularly in low biomass samples [38]. The reason for the much lower bacterial loads observed here is uncertain, but may be related to inhibition in our qPCR analyses, as discussed above. Nevertheless, higher bacterial loads were generally associated with relatively homogeneous bacterial communities across replicates of the same sample, though diversity estimates (chao1) appeared unrelated to bacterial load between samples (Table 1). A larger number of capsule community analyses would be required to properly test these relationships, or lack thereof.

Microbial communities associated with contracted capsules are comprised of a few relatively abundant community members that are broadly distributed across multiple capsules, as well as a broad suite highly variable, low abundance members. Microbial communities associated with contracted capsules are comprised of 24–664 species (chao 1) and are similar in diversity to healthy breast tissue (121 taxa [39], 125–130 [40]) but far less diverse than, for example the, $10^3$ species commonly found in the human gut [41], $10^4$ species on human skin [42], or the $>10^4$ species common in soils [43]. Our analyses suggest that capsule microbiomes are more diverse than what previous amplicon-based sequencing observations suggest, given that these studies found on average only 8 bacterial species per capsule biofilm [30]. Again, these differences likely reflect methodological variation and could be related to DNA extraction, the region of the 16S rRNA gene targeted for amplification, or depth of sequence. In our study, most capsule community members belong to the Actinobacteria, Firmicutes, and Proteobacteria, with a minor component from the Bacteroidetes (Fig 2A). These same four phyla were previously recovered from breast tissues removed from healthy women and women with benign and malignant tumors [39, 44–46], as well as from heavily contracted capsules [30], including those associated with BIA ALCL [47]. Analyses at higher taxonomic resolution.
(genus level) show that while 20% of the capsule microbial communities were dominated by *Staphylococcus* sp., the remaining capsule community members comprised 4 additional principle taxa that were both greater than 1% average abundance across all capsules and present in more than 40% of the capsules studied. These belong to the Firmicutes, Proteobacteria, and Actinobacteria, demonstrating the importance of multiple other taxonomic groups to capsule communities. *Staphylococcus* sp. are frequently cultured from contracted capsules [18, 19] and are indeed prevalent (15 of 24) in the capsules we analyzed through amplicon sequencing, but many of the other abundant species have not been widely reported in previous culture-based studies of contracted capsules, illustrating the utility of culture-independent analyses.

---

**Fig 3. Bacterial isolates from capsule samples.** (a) Bacteria commonly associated with human tissue. Phylogeny is based on the 16S rRNA gene. Dark wedges indicate bacteria we isolated from breast implant capsules; (b, c) Phylogeny of 16S rRNA gene sequences from our isolates (b) Firmicutes, (c) Actinobacteria. Displayed trees (b) and (c) were constructed in Arb using maximum likelihood. Filled circles indicate bootstrap support (maximum parsimony, with 100 resamplings) of ≥ 90%, and open circles represent ≥ 75% support. Bar, 5% sequence divergence. 

https://doi.org/10.1371/journal.pone.0249261.g003

**Fig 4. Hierarchical clustering analysis.** Hierarchical relationship among samples based on Euclidean distance of 16S-OTU abundances. The UPGMA clustering algorithm was used to obtain the hierarchical relationships between samples. Node labels indicate the sample ID. Note sample C8R and C14R were excluded from rarefaction analysis as the samples had half the number of total sequence reads compared to other samples. Circle color: Green = Smooth Round Gel; Blue = Textured Gel (round or anatomical); Brown = Smooth Round Saline. B stands for Baker.

https://doi.org/10.1371/journal.pone.0249261.g004
relative prevalence of many of these predominant taxa across all samples collected implies that these taxa likely represent common implant colonizers with potential for biofilm formation. Of the species with >1% average abundance across all samples, some have been reported as skin commensals like the *Staphylococcus* sp. [42, 48], but many others including: *Rhodococcus* sp., *Bacillales* sp., *Cutibacterium* sp., *Haemophilus* sp., *Kocuria* sp., *Finegoldia* sp., and *Escherichia-shigella* sp., are not commonly reported as part of the healthy skin microbiome [48, 49] and instead may be opportunistic pathogens [50–53]. The majority of the species present below 1% abundance varied widely between samples and also within the same patient between left and right capsules. These microbial community members tend to be overwhelmed by the more common and abundant community members when bacterial loads are qualitatively high. This suggests that lower sensitivity analyses with partial DNA extraction yields, strong PCR inhibition, or shallow depth of sequence, might miss important biofilm community members. Our data implies that in addition to the group of highly abundant Firmicutes, Proteobacteria, and Actinobacteria, capsule communities consist of highly variable low relative abundance members.

Our isolate collection is comprised exclusively of members of the Firmicutes and Actinobacteria, missing entirely the Proteobacteria and Bacteroidetes detected through culture-independent community profiling, and revealing the expected bias in the organisms cultivated. At higher taxonomic resolution, our isolates were identified as *Rhodococcus* sp., *Bacillus* sp., *Staphylococcus* sp., and *Micrococcus* sp. With the exception of the *Rhodococcus* sp. (Fig 3B and 3C), organisms from these genera have been detected in previous cultivation-based studies. Notably, *Rhodococcus* species are the most abundant member of the capsule community from C2R, from which it was isolated, giving confidence that some relevant, yet new, organisms can be brought under laboratory culture using enrichment-isolation approaches standard to classical microbiology.

To compare our isolates to other studies with greater resolution, we conducted phylogenetic analyses of the full-length 16S rRNA genes recovered from our isolates. These phylogenetic analyses reveal that even cultivation-based approaches recover a diversity of organisms distinct at the species level (97% identity in the 16S rRNA gene). Organisms of the same species are well known to exhibit differences in genomic composition and metabolic potential—*Escherichia coli* is a classic example with up to 60% non-redundant genomic information across 3 ecologically diverse strains [54]. Notably, none of our isolates belong to the *S. epidermidis* or *S. aureus* species commonly implicated in capsular contracture [22, 35, 36]. Instead, our isolates are distributed across the *Staphylococcus* genus including organisms most closely related to *S. hominis*, *S. kloosii*, and *S. petrasii* sp. that can be associated with the human skin microbiome [42], but also have been implicated in pathogenesis [55, 56]. These isolates may thus provide systems with which to interrogate microbial physiology relevant to capsule biofilm formation and contracture.

We evaluated relationships between implant type, plane of placement, Baker contracture grade, and microbial community composition through hierarchical clustering analyses (Fig 4). In hierarchical clustering, differences in microbial community composition between groupings result in branching patterns whereby capsules from a specific individual group cluster together. Capsules recovered from the left and right breasts of the same patient tend to cluster together, particularly for C7, C2R, and C1L, with C4R exhibiting more spread. Importantly, left and right capsules do not cluster together, which implies that the microbial communities in the left and right capsules are distinct and likely not regulated by the same factors, like patient history or skin microbiome. Microbial community composition, furthermore, does not tend to cluster according to implant type or Baker scale of
capsular contracture, suggesting that other variables may also contribute to determining the specific composition of microbial communities associated with contracted capsules. These observations should be tempered given the limited number of observations in the current study and improved statistics from a larger number of patients may help reveal relationships between microbial community composition, implant type, and capsular contracture.

Conclusions

Our analyses reveal that microbial communities associated with pathologic and non-pathologic contracted capsules are considerably more diverse than previously appreciated. Taxa from 4 main phyla- the Proteobacteria, Actinobacteria, Firmicutes, and Bacteroidetes- are most commonly present and at appreciable relative abundances. This observation is consistent across multiple other cultivation dependent and cultivation independent studies. By contrast, however, we also find a number of other taxa that are generally present at variable and low relative abundances that sometimes can represent appreciable fractions of the community. This result appears to contrast with previous studies, but reveals that methodological variability across studies may lead to differing results and conclusions. This highlights a need for the cosmetic surgery community to develop standards of best practice if amplicon sequencing approaches are to be adopted in research and clinical practice, more broadly. In particular, these standards should: 1) address contamination; 2) select regions of the 16S rRNA or other genes to be used; 3) optimize DNA extraction and amplification protocols; 4) establish minimum information standards for metadata; and 5) develop consensus on sequencing platforms and depth. Our findings, that capsule associated microbial communities are diverse and highly variable, suggests that mitigation of microbial capsule colonization could be best addressed through personized approaches that consider the broader patient microbiome. As noted above, however, standards of best practice across the community could promote further research, by multiple groups, that would be needed to dramatically increase the number of observations and provide the statistical power needed to establish cause and effect relationships.

Material and methods

Ethical approval

Ethics approval for this study was obtained through the University of British Columbia Clinical Research Ethics Board under “Biofilm Study” H16-01002.

Sample collection

Capsule samples analysed in this study were all collected in the private practice of author NJC from patients that underwent revision surgery consisting of implant exchange or removal. The sample series represents 17 consecutive cases between February of 2015 and June of 2016. All capsule specimens were collected from aesthetic patients except capsule 1, which was collected from a reconstruction surgery. Given that a goal of this study was to examine biofilm composition across a range of pathological and non-pathological capsules, we analysed a suite of samples that varied from Baker grade I to IV. Reasons for surgery included implant malposition, implant rupture, pathological capsular contracture, or patient desire to change implant type. Capsular tissue samples were removed aseptically from the patient and placed separately in sterile containers, containing saline. In most cases one sample was taken from a visually representative area of the capsule of each implant. In one case, C14, an additional sample was taken from one of the implant capsules because of the presence of the distinctly different appearance
in areas of the capsule surrounding the implant. The implants were processed for microbiological analysis within approximately 24 hours of removal.

**Cultivation and isolation**

Aseptically cut tissue sections were swabbed for culturing onto LB agar. Plates were incubated at 37°C for 1–7 days. Pure colonies selected for sequencing were grown up overnight in LB broth at 37°C, then lysed at 95°C for 30 minutes. 1 μl of lysed sample was used in the PCR with the universal primers 27F/1492R, to amplify full-length bacterial 16SrRNA genes. PCR amplifications were carried out with the following cycling conditions: initial denaturing at 95°C for 3 min, 30 cycles of 95°C for 30 s, 48°C for 30 s, and 72°C for 60 s, followed by a final elongation step at 72°C for 10 min. PCR products were Sanger sequenced with forward and reverse primers (27F/1492R) by GeneWiz LLC.

**Sample processing and DNA extraction**

Microbial DNA was extracted from approximately 0.25 g of breast capsular tissue using the Mobio PowerMax™ Soil DNA Isolation Kit, as per manufacturer’s instructions. Resulting DNA was stored at -20°C. The quality and quantity of genomic DNA were measured on a NanoDrop™ ND-1000 spectrophotometer (Thermo Scientific) and by PicoGreen (Quant-iT dsDNA kit, Invitrogen).

**SSU rRNA gene amplification and iTag sequencing**

Bacterial and archaeal 16S rRNA gene fragments from the extracted genomic DNA were amplified using primers 515F and 806R. Sample preparation for amplicon sequencing was performed as described as [57]. In brief, the aforementioned 16S rRNA gene-targeting primers, complete with Illumina adapter, an 8-nt index sequence, a 10-nt pad sequence, a 2-nt linker and the gene specific primer were used in equimolar concentrations together with dNTPs, PCR buffer, MgCl₂ 2 U/μl high fidelity Platinum Taq DNA polymerase and PCR-certified water to a final volume of 50 μL. PCR amplification was performed with an initial denaturing step of 95°C for 2 min, followed by 30 cycles of denaturation (95°C for 20 s), annealing (55°C for 15 s), and elongation (72°C for 5 min), with a final elongation step at 72°C for 10 min. A nested-PCR approach, using primers 27F and 1492R for the initial amplification, followed by a second amplification using primer pair 515F/806R under the conditions outlined above, was adopted for samples in which the original PCR did not yield any products. Equimolar concentrations of prepared amplicon samples were pooled into a single library by using the Invitrogen SequaPrep kit. The amplicon library was analysed on an Agilent Bioanalyzer using the High Sensitivity dsDNA assay to determine approximate library fragment size, and to verify library integrity. Pooled library concentration was determined using the KAPA Library Quantification Kit for Illumina. Library pools were diluted to 4 nM and denatured into single strands using fresh 0.2 N NaOH as recommended by Illumina. The final library was loaded at a concentration of 8 pM, with an additional PhiX spike-in of 5–20%. Sequencing was conducted at the University of British Columbia Sequencing and Bioinformatics Consortium (http://sequencing.ubc.ca) All raw sequence data (including blanks) were submitted to the SRA database under accession PRJNA632935.

Bacterial DNA was quantified by quantitative polymerase-chain reaction (qPCR) using the SsoFast™ EvaGreen assay (Bio-Rad™) and a CFX96 Real-Time Detection System (Bio-Rad™). The 16S rRNA gene was targeted using bacterial-specific primers, 27F, (5′-AGAGTTT-GATCCTGGCTCAG) and DW519R (5′-GNTT TACCGCGGCKGCTG). Each amplification reaction (20 μL) contained PCR certified water (4 μL), SsoFast™ EvaGreen master-mix (10 μL), and
3 μM primer (2 μL). Amplification of the 16S rRNA gene was performed with an initial denaturation step (95˚C, 3 min), followed by 45 cycles of denaturation (95˚C, 20s); annealing (55˚C, 30s); and elongation (72˚C, 30s). This was followed by a melt curve analysis for assessing amplicon specificity (ramp-up of 0.5˚C every second, increasing from 55˚C to 95˚C). Bacterial DNA standards, ranging from $10^2$–$10^8$, non-template controls, and sample DNA were all run in duplicate. The qPCR assays were tested for inhibition by adding known copies of E. Coli 16S rRNA genes and comparing the resulting measured copy numbers to the expected copy numbers.

16S rRNA amplicon sequence data analysis and visualization

Sequences were processed using Mothur and the Miseq protocol [58]. Sequences were removed from the analysis if they contained ambiguous characters, had homopolymers longer than 8 bp, and did not aligned to a reference alignment of the correct sequencing region. Unique sequences and their frequency in each sample were identified, and a pre-clustering algorithm was used to further de-noise sequences within each sample [59]. Unique sequences were identified and aligned against a SILVA (v.132) alignment (available at http://www.mothur.org/wiki/Silva_reference_alignment). Sequences were chimera checked using VSEARCH [60] and reads were clustered into 97% OTUs based on uncorrected pairwise distance matrices. OTUs were classified using SILVA reference taxonomy database (release v.132, available at http://www.mothur.org/wiki/Silva_reference_files). All data was visualized in RStudio (RStudio Team, 2015) [61]. For generation of Chao1 and Hierarchical clustering the number of reads per sample was rarefied to 8494 sequences per sample. Samples C8R and C14R were excluded from these analyses as their read number was lower (4848 and 5099 respectively).

Full-length 16S analysis

Full-length 16S rRNA sequences were quality checked using the Sequencher software package (version 5.2, GeneCodes Corporation, Ann Arbor, MIUSA http://www.gene codes.com). 16S rRNA gene sequences were compared to available databases using the Basic Local Alignment Search Tool (BLAST) [62]. To determine approximate phylogenetic affiliations, sequences were aligned using the SINA Web Aligner [63] then imported into the ARB programme package for manual editing using the SILVA database [64]. All subsequent phylogenetic analyses were performed in ARB [65]. Maximum likelihood algorithms were used to calculate a phylogenetic tree, with maximum parsimony-based bootstraps (100 re-samplings) also calculated to assess the stability of observed branching patterns.

Author Contributions

Conceptualization: Sean A. Crowe, Nick Carr.
Data curation: Sean A. Crowe, Rachel L. Simister, Jenifer S. Spence, Peter Lennox, Nick Carr.
Formal analysis: Sean A. Crowe.
Funding acquisition: Sean A. Crowe, Paul A. Kenward, Peter Lennox, Nick Carr.
Investigation: Sean A. Crowe, Rachel L. Simister, Jenifer S. Spence, Paul A. Kenward, Peter Lennox, Nick Carr.
Methodology: Sean A. Crowe, Rachel L. Simister, Jenifer S. Spence, Paul A. Kenward, Peter Lennox, Nick Carr.
Project administration: Sean A. Crowe.

Resources: Sean A. Crowe, Peter Lennox, Nick Carr.

Software: Sean A. Crowe.

Supervision: Sean A. Crowe, Rachel L. Simister.

Validation: Sean A. Crowe, Rachel L. Simister, Nick Carr.

Visualization: Sean A. Crowe, Rachel L. Simister, Jenifer S. Spence.

Writing – original draft: Sean A. Crowe.

Writing – review & editing: Sean A. Crowe, Rachel L. Simister, Jenifer S. Spence, Paul A. Kenward, Aaron C. Van Slyke, Peter Lennox, Nick Carr.

References

1. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016; 14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533 PMID: 27541692; PubMed Central PMCID: PMC4991899.

2. Consortium IHGS. Finishing the euchromatic sequence of the human genome. Nature. 2004; 431 (7011):931–45. https://doi.org/10.1038/nature03001 PMID: 15496913

3. Tumbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JJ. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027–31. https://doi.org/10.1038/nature05414 PMID: 17183312.

4. Huang YJ, Charlson ES, Collman RG, Colombini-Hatch S, Martinez FD, Senior RM. The role of the lung microbiome in health and disease. A National Heart, Lung, and Blood Institute workshop report. Am J Respir Crit Care Med. 2013; 187(12):1382–7. https://doi.org/10.1164/rccm.201303-0488WS PMID: 23614695; PubMed Central PMCID: PMC5155250.

5. Ahn J, Sinha R, Pei Z, Dominianii C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013; 105(24):1907–11. https://doi.org/10.1093/jnci/djt300 PMID: 24316595; PubMed Central PMCID: PMC3866154.

6. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science. 2010; 330(6012):1768–73. https://doi.org/10.1126/science.1195568 PMID: 21204699; PubMed Central PMCID: PMC3159383.

7. Consortium HMP. Structure, function and diversity of the healthy human microbiome. nature. 2012; 486 (7402):207. https://doi.org/10.1038/nature11234 PMID: 22699609

8. Greenblum S, Chiu H-C, Levy R, Carr R, Borenstein E. Towards a predictive systems-level model of the human microbiome: progress, challenges, and opportunities. Current opinion in biotechnology. 2013; 24(4):810–20. https://doi.org/10.1016/j.copbio.2013.04.001 PMID: 23623295

9. Levy R, Borenstein E. Metabolic modeling of species interaction in the human microbiome elucidates community-level assembly rules. Proceedings of the National Academy of Sciences. 2013; 110 (31):12804–9. https://doi.org/10.1073/pnas.1309261110 PMID: 23858463

10. de la Fuente-Núñez C, Reffuveille F, Fernández L, Hancock RE. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Current opinion in microbiology. 2013; 16(5):580–9. https://doi.org/10.1016/j.mib.2013.06.013 PMID: 23880136

11. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003; 2 (2):114–22. https://doi.org/10.1038/nrd1008 PMID: 12563302.

12. del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007; 82(2):204–9. https://doi.org/10.1038/sj.cpt.6100247 PMID: 17538551.

13. Deva AK, Adams WP Jr, Vickery K. The role of bacterial biofilms in device-associated infection. Plastic and reconstructive surgery. 2013; 132(5):1319–28. https://doi.org/10.1097/PRS.0b013e3182a3c105 PMID: 23924649

14. Pace NR. A molecular view of microbial diversity and the biosphere. Science. 1997; 276(5313):734–40. https://doi.org/10.1126/science.276.5313.734 PMID: 9115194

15. Binladen J, Gilbert MTP, Bollback JP, Panitz F, Bendixen C, Nielsen R, et al. The use of coded PCR primers enables high-throughput sequencing of multiple homolog amplification products by 454 parallel sequencing. PloS one. 2007; 2(2):e197. https://doi.org/10.1371/journal.pone.0000197 PMID: 17299583
16. Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012; 489(7415):250. https://doi.org/10.1038/nature11553 PMID: 22972298

17. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome medicine. 2016; 8(1):51. https://doi.org/10.1186/s13073-016-0307-y PMID: 27122046

18. Ajdic D, Zoghi B, Gerth D, Panthaki ZJ, Thaller S. The Relationship of Bacterial Biofilms and Capsular Contracture in Breast Implants. Aesthet Surg J. 2016; 36(3):297–309. https://doi.org/10.1093/asjs/ sjv177 PMID: 26843099; PubMed Central PMCID: PMCP5127460.

19. Del Pozo JL, Tran NV, Petty PM, Johnson CH, Walsh MF, Bite U, et al. Pilot study of association of bacteria on breast implants with capsular infection. J Clin Microbiol. 2009; 47(5):1333–7. https://doi.org/10.1128/JCM.00096-09 PMID: 19261794; PubMed Central PMCID: PMCP2681843.

20. Silverman BG, Brown SL, Bright RA, Kaczmarek RG, Arrowsmith-Lowe JB, Kessler DA. Reported complications of silicone gel breast implants: an epidemiologic review. Annals of internal medicine. 1996; 124(8):744–56. https://doi.org/10.7326/0003-4819-124-8-199604150-00008 PMID: 8633836

21. Tamhoto H, Vickery K, Deva AK. Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammoplasty. Plast Reconstr Surg. 2010; 126(3):835–42. https://doi.org/10.1097/PRS.0b013e3181e3b456 PMID: 20811216.

22. Seng P, Bayle S, Alieez A, Romain F, Casanova D, Stein A. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and reconstructive surgery in the south of France. International Journal of Infectious Diseases. 2015; 35:62–6. https://doi.org/10.1016/j.ijid.2015.04.010 PMID: 25910855

23. Fitzal F, Turner SD, Kenner L. Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery? Open biology. 2019; 9(4):190006. https://doi.org/10.1098/rsob.190006 PMID: 30939983

24. Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, et al. Bacterial biofilm infection detected in breast implant–associated anaplastic large-cell lymphoma. Plastic and reconstructive surgery. 2016; 137(6):1659–69. https://doi.org/10.1097/PRS.0000000000002010 PMID: 26890506

25. Collett DJ, Raikhurst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current risk estimate of breast implant–associated anaplastic large cell lymphoma in textured breast implants. Plastic and reconstructive surgery. 2019; 143(3S):30S–40S. https://doi.org/10.1097/PRS.0000000000005567 PMID: 30817554

26. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. The lancet. 2001; 358(9276):135–8. https://doi.org/10.1016/S0140-6736(01)05321-1 PMID: 11463434

27. Blount AL, Martin MD, Lineberry KD, Kettaneh N, Alfonso DR. Capsular contracture rate in a low-risk population after primary augmentation mammoplasty. Aesthetic surgery journal. 2013; 33(4):516–21. https://doi.org/10.1177/1090820X13484465 PMID: 23636624

28. Giordano S, Peltoniemi H, Lilius P, Salmi A. Povidone-iodine combined with antibiotic topical irrigation to reduce capsular contracture in cosmetic breast augmentation: a comparative study. Aesthetic surgery journal. 2013; 33(5):675–80. https://doi.org/10.1177/1090820X13491490 PMID: 23757043

29. Pajkos A, Deva AK, Vickery K, Cope C, Chang L, Cossart YE. Detection of subclinical infection in significant breast implant capsules. Plast Reconstr Surg. 2003; 111(5):1605–11. https://doi.org/10.1097/01.PRS.0000054768.14922.44 PMID: 12655204.

30. Cook J, Holmes CJ, Wixtrom R, Newman MI, Pozner J. Characterizing the Microbiome of the Contracted Breast Capsule Using Next Generation Sequencing. Aesthetic Surgery Journal. 2020.

31. Bachour Y, Poort L, Verweij SP, van Selms G, Winters HA, Ritt MJ, et al. PCR characterization of micro-

32. Frebourg NB, Lefebvre S, Baert S, Lemeland JF. PCR-Based assay for discrimination between invasive and contaminating Staphylococcus epidermidis strains. J Clin Microbiol. 2000; 38(2):877–80. https://doi.org/10.1128/JCM.38.2.877-880.2000 PMID: 10655405; PubMed Central PMCID: PMCP86232.

33. Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clinical microbiology reviews. 1994; 7(1):117–40. https://doi.org/10.1128/CMR.7.1.117 PMID: 8118787

34. Kotilainen P. Association of coagulase-negative staphylococcal slime production and adherence with the development and outcome of adult septicemias. Journal of clinical microbiology. 1990; 28(12):2779–85. https://doi.org/10.1128/JCM.28.12.2779-2785.1990 PMID: 2280010

35. Shah Z, Lehman JA Jr, Tan J. Does Infection Play a Role in Breast Capsular Contracture? Plastic and reconstructive surgery. 1981; 68(1):34–8. https://doi.org/10.1097/00006534-198107000-00007 PMID: 7243998

36. Rieger UM, Mesina J, Kalbermatten DF, Haug M, Frey HP, Pico R, et al. Bacterial biofilms and capsular contracture in patients with breast implants. British Journal of Surgery. 2013; 100(6):768–74. https://doi.org/10.1002/bjs.9084 PMID: 23468161
Chaves F, García-A, Welch R, Burland V, Plunkett G, Redford P, Roesch P, Rasko D, et al. Extensive mosaic structure.

Boisrenoult P. Cutibacterium acnes prosthetic joint infection: diagnosis and treatment.

Bottone EJ. Bacillus cereus, a volatile human pathogen.

Prescott JF. Rhodococcus equi: an animal and human pathogen.

Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu W-H, et al. The human oral microbiome.

Byrd AL, Belkaid Y, Segre JA, et al. Biogeography and individuality shape function in the human skin metagenome.

Oh J, Byrd AL, Deming C, Conian S, Kong HH, Segre JA, et al. Geographical and individuality shape function in the human skin metagenome.

Van Der Heijden MG, Bardgett RD, Van Straalen NM. The unseen majority: soil microbes as drivers of plant diversity and productivity in terrestrial ecosystems.

Urbania C, Gloor GB, Brackstone M, Scott L, Tangey M, Reid G. The Microbiota of Breast Tissue and Its Association with Breast Cancer.

Spear SL, Baker JL Jr. Classification of capsular contracture after prosthetic breast reconstruction. Plastic and reconstructive surgery.

Salt SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC biology.

Urbania C, Gloor GB, Brackstone M, Scott L, Tangey M, Reid G. The Microbiota of Breast Tissue and Its Association with Breast Cancer. Appl Environ Microbiol. 2016; 82(16):5039–48. https://doi.org/10.1128/AEM.01235-16 PMID: 27342554; PubMed Central PMCID: PMC4968547.

Meng S, Chen B, Yang J, Meng Q, Zhang L. Study of microbiomes in aseptically collected samples of human breast tissue using needle biopsy and the potential role of in situ tissue microbiomes for promoting malignancy. Frontiers in oncology. 2018; 8:318. https://doi.org/10.3389/fonc.2018.00318 PMID: 30175072.

Walker JN, Hanson BM, Pinkner CL, Simar SR, Pinkner JS, Parikh R, et al. Insights into the microbiome of breast implants and periprosthetic tissue in breast implant-associated anaplastic large cell lymphoma. Scientific reports.

Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, et al. Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Plast Reconstr Surg. 2016; 137(6):1659–69. https://doi.org/10.1097/PRS.0000000000002010 PMID: 26890566.

Grice EA, Kong HH, Conian S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. science. 2009; 324(5931) :1190–2. https://doi.org/10.1126/science.1171700 PMID: 19478181.

Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nature Reviews Microbiology. 2018; 16 (3):143. https://doi.org/10.1038/nmicro.2017.157 PMID: 29332945.

Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu W-H, et al. The human oral microbiome. Journal of bacteriology. 2010; 192(19):5002–17. https://doi.org/10.1128/JB.00542-10 PMID: 20656903.

Prescott JF. Rhodococcus equi: an animal and human pathogen. Clinical microbiology reviews. 1991; 4 (1):20–34. https://doi.org/10.1128/cmr.4.1.20 PMID: 2004346.

Bottone EJ. Bacillus cereus, a volatile human pathogen. Clinical microbiology reviews. 2010; 23 (2):382–98. https://doi.org/10.1128/CMR.00073-09 PMID: 20375358.

Boisrenoult P. Cutibacterium acnes prosthetic joint infection: diagnosis and treatment. Orthopaedics & Traumatology: Surgery & Research. 2018; 104(1):S19–S24. https://doi.org/10.1016/j.otsr.2017.05.030 PMID: 29203432.

Welch R, Burland V, Plunkett G, Redford P, Roesch P, Rasko D, et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proceedings of the National Academy of Sciences. 2002; 99(26):17020–4. https://doi.org/10.1073/pnas.252529799 PMID: 12471157.

Švec P, De Bel A, Sedliaček I, Petráš P, Gelbičová T, Černohůvková J, et al. Staphylococcus petrasii subsp. pragensis subsp. nov., occurring in human clinical material. International journal of systematic and evolutionary microbiology. 2015; 65(7):2071–7. https://doi.org/10.1099/ijs.0.00220 PMID: 25829332.

Chaves F, García-Alvarez M, Sanz F, Alba C, Otero JR. Nosocomial spread of a Staphylococcus hominis subsp. novobiocinicus strain causing sepsis in a neonatal intensive care unit. Journal of clinical microbiology. 2005; 43(9):4877–9. https://doi.org/10.1128/JCM.43.9.4877-4879.2005 PMID: 16145165.
57. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Applied and environmental microbiology. 2013; 79(17):5112–20. https://doi.org/10.1128/AEM.01043-13 PMID: 23793624

58. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Applied and environmental microbiology. 2009; 75(23):7537–41. https://doi.org/10.1128/AEM.01541-09 PMID: 19801464

59. Schloss PD, Gevers D, Westcott SL. Reducing the effects of PCR amplification and sequencing artifacts on 16S rRNA-based studies. PloS one. 2011; 6(12):e27310. https://doi.org/10.1371/journal.pone.0027310 PMID: 22194782

60. Rognes T, Flouri T, Nichols B, Quince C, Mahé F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016; 4:e2584. https://doi.org/10.7717/peerj.2584 PMID: 27781170

61. Team R. RStudio: integrated development for R. RStudio, Inc, Boston, MA URL http://www.rstudio.com. 2015.

62. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990; 215(3):403–10. https://doi.org/10.1016/S0022-2836(05)80360-2 PMID: 2231712.

63. Pruesse E, Peplies J, Glockner FO. SINA: accurate high-throughput multiple sequence alignment of ribosomal RNA genes. Bioinformatics. 2012; 28(14):1823–9. https://doi.org/10.1093/bioinformatics/bts252 PMID: 22556368; PubMed Central PMCID: PMC3389763.

64. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, et al. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 2007; 35(21):7188–96. https://doi.org/10.1093/nar/gkm864 PMID: 17947321; PubMed Central PMCID: PMC2175337.

65. Ludwig W, Strunk O, Westram R, Richter L, Meier H, Yadhukumar, et al. ARB: a software environment for sequence data. Nucleic Acids Res. 2004; 32(4):1363–71. https://doi.org/10.1093/nar/gkh293 PMID: 14985472; PubMed Central PMCID: PMC390282.